Compare NGS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | INBX |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.9M | 430.2M |
| IPO Year | 2002 | 2020 |
| Metric | NGS | INBX |
|---|---|---|
| Price | $33.77 | $77.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $35.67 | N/A |
| AVG Volume (30 Days) | 93.1K | ★ 253.2K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 14.85 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $166,824,000.00 | $1,400,000.00 |
| Revenue This Year | $9.83 | $563.00 |
| Revenue Next Year | $14.49 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $16.73 | $10.81 |
| 52 Week High | $34.57 | $94.57 |
| Indicator | NGS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 46.42 |
| Support Level | $32.36 | $76.10 |
| Resistance Level | $34.57 | $81.79 |
| Average True Range (ATR) | 1.03 | 6.10 |
| MACD | -0.03 | -1.31 |
| Stochastic Oscillator | 79.74 | 14.90 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.